News | Careers |Contact
Global

TOP CDMO MNC！Great Bay Bio Add One More Overseas Order

2023-12-19

继生命科学、特种化工等跨国企业（MNC）之后，大湾生物与医药CDMO领域顶级MNC正式达成长期、面向未来的合作。大湾生物卓越的培养基开发平台结合该MNC一体化的研发生产供应链，为全球无血清培养基市场产业发展与升级，注入澎湃活力，双方共同开拓价值数十亿美元的细胞培养基市场。


大湾生物与医药CDMO领域顶级MNC正式达成长期、面向未来的合作


此次合作背景基于大湾生物智能化技术平台在细胞培养基开发板块强大的开发能力与该MNC完善的研发生产供应链。


大湾生物智能化培养基数据库平台（AlfaMedX）根据该MNC终端客户不同产品需求，提供定制化的培养基，结合智能化无筛选培养基开发平台（AlfaOPA）对现有细胞培养基成分进行深度优化调节，充分挖掘细胞成长潜力，将产品表达量与质量提升至天花板。大湾生物技术创新且商业实用的平台赋能该MNC高效完成终端客户需求，提供高质量服务的同时缩短产品上市时间，促进商业化。

该MNC作为医药CDMO市场领导者，在全球有着完善的产业供应链。依托该MNC，大湾生物智能化技术平台充分应用于药物研发不同阶段的培养基开发及工艺优化、培养基供应，让全球生物工艺开发更简单更高效，加速推进全球生命科学领域科研与产业进步。
Back
Recent News
Great Bay Bio Establishes Strategic Partnership with a Global Leading Biosimilar Enterprise to Accelerate Global Adoption of AlfaCell Platform

Great Bay Bio Establishes Strategic Partnership with a Global Leading Biosimilar Enterprise to Accelerate Global Adoption of AlfaCell Platform

2026-05-20
Great Bay Bio’s AlfaCell Delivers Average Titer Above 6.9 g/L Across Client Projects, with RCB Completed in Just 1.5 Months

Great Bay Bio’s AlfaCell Delivers Average Titer Above 6.9 g/L Across Client Projects, with RCB Completed in Just 1.5 Months

2026-03-27
Great Bay Bio Recognized in the Deloitte Greater Bay Area Technology Fast 40 & Rising Star Program, Receiving Further Authoritative Recognition for AI-Enabled Bioprocess Innovation

Great Bay Bio Recognized in the Deloitte Greater Bay Area Technology Fast 40 & Rising Star Program, Receiving Further Authoritative Recognition for AI-Enabled Bioprocess Innovation

2026-03-26
Global Bioprocessing Made Simpler and More Efficient
Schedule a Meeting

Schedule a Meeting

I agree to the privacy policy.

Submit
COPYRIGHT 2026 © Great Bay Bio ALL RIGHTS RESERVD.